Search research articles
Contact Us
Filters
Showing results (451-460 of 483) with videos related to
Page
of 49
Sort By:
The Lancet. Oncology
|
July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff, Lisa G Horvath, Karen Autio, et al.
The Lancet. Haematology
|
July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
Richard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Blood
|
May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Cell Communication and Signaling : CCS
|
September 2, 2024
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis
Michela Luciano, Helene Sieberer, Peter W Krenn, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Leukemia
|
May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Peter Paschka, Richard F Schlenk, Daniela Weber, et al.
The New England Journal of Medicine
|
December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Page
of 49
Search research articles
Search
Showing results (451-460 of 483) with videos related to
Sort By:
Page
of 49
The Lancet. Oncology
|
July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff, Lisa G Horvath, Karen Autio, et al.
The Lancet. Haematology
|
July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
Richard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Blood
|
May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Sherko Kuemmel, Mario Campone, Delphine Loirat, et al.
Cell Communication and Signaling : CCS
|
September 2, 2024
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis
Michela Luciano, Helene Sieberer, Peter W Krenn, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Leukemia
|
May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Peter Paschka, Richard F Schlenk, Daniela Weber, et al.
The New England Journal of Medicine
|
December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Page
of 49